Interactions of serum hsCRP with apoB, apoB/AI ratio and some components of metabolic syndrome amplify the predictive values for coronary artery disease

Clinical Biochemistry

Volumn 39, Issue 10, 2006, Pages 971-977

  Rasouli, Mehdi ^a   Kiasari, Asadollah Mohseni ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CAD; Cholesterol; Diabetes mellitus; hsCRP; Hypertension; Metabolic syndrome

Indexed keywords

ALBUMIN; ALPHA 2 GLOBULIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; GLOBULIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INFLAMMATION; LEUKOCYTE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; NEUTROPHIL; PREDICTION AND FORECASTING; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX;

ADULT; AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; C-REACTIVE PROTEIN; CHOLESTEROL; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 33748973228     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2006.07.003     Document Type: Article

References (39)

1. Grundy S.M., Pasternak R., Greenland P., Smith S., and Fuster V. Assessment of cardiovascular risk by use of multiple risk factor assessment equations. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J. Am. Coll. Cardiol. 34 (1999) 1348-1359
2. Tiong A.Y., and Brieger D. Inflammation and coronary heart disease. Am. Heart J. 150 (2005) 11-18
3. Danesh J., Collins R., Appleby P., and Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA 279 (1998) 1477-1483
4. Zebrack J.S., Muhlestein J.B., Horne B.D., and Anderson J.L. C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J. Am. Coll. Cardiol. 39 (2002) 632-639
5. Folsom A.R., Aleksic N., Catellier D., Juneja H.S., and Wu K.K. C-Reactive protein and incident coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Am. Heart J. 144 (2002) 233-238
6. Levinson S.S., Miller J.J., and Elin R.J. Poor predictive value of hsCRP indicates need for reassessment. Clin. Chem. 50 (2004) 1733-1735
7. Zebrack J.S., Anderson J.L., Maycock C.A., Horne B.D., Bair T.L., and Muhlestein J.B. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am. J. Cardiol. 89 (2002) 145-149
8. Danesh J., Wheeler J.G., Hirschfield G.M., Eda S., Eiriksdottir G., Rumley A., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350 (2004) 1387-1397
9. Visser M., Bouter L.M., McQuillan G.M., Wener M.H., and Harris T.B. Elevated C-reactive protein levels in overweight and obese adults. JAMA 282 (1999) 2131-2135
10. Aronson D., Goldberg A., Rogium A., Petcherski S., Rimer D., Gruberg L., et al. Effect of obesity on the relationship between C-reactive protein and coronary artery stenosis in patients with stable angina. Atherosclerosis 185 (2006) 137-142
11. Florez H., Castillo-Florez S., Mendez A., Casanova-Romero P., Larreal-Urdaneta C., Lee D., et al. C-reactive protein is elevated in obese patients with the metabolic syndrome. Diabetes Res. Clin. Pract. 71 (2006) 92-100
12. Ridker P.M., Rifai N., Cook N.R., Bradwin G., and Buring J.E. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 294 (2005) 326-333
13. Li J.J., Jiang H., Huang C.X., Fang C.H., Tang Q.Z., Xia H., et al. Elevated level of plasma C-reactive protein in patients with unstable angina: its relations with coronary stenosis and lipid profile. Angiology 53 (2002) 265-272
14. Pirro M., Siepi D., Lupattelli G., Roscini A.R., Schillaci G., Gemelli F., et al. Plasma C-reactive protein in subjects with hypo/hyperalphalipoproteinemias. Metabolism 52 (2003) 432-436
15. Schulze M.B., Rimm E.B., Li T., Rifai N., Stampfer M.J., and Hu F.B. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care 27 (2004) 889-894
16. Aronson D., Bartha P., Zinder O., Kerner A., Shitman E., Markiewicz W., et al. Association between fasting glucose and C-reactive protein in middle-aged subjects. Diabet. Med. 21 (2004) 39-44
17. Freeman D.J., Norrie J., Caslake M.J., Gaw A., Ford I., Lowe G.D., et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention study. Diabetes 51 (2002) 1596-1600
18. Kang E.S., Kim H.J., Kim Y.M., Lee S., Cha B.S., Lim S.K., et al. Serum C-reactive protein is associated with carotid intima-media thickness in type 2 diabetes. Diabetes Res. Clin. Pract. 66 (2004) S115-S120
19. Schillaci G., Pirro M., Gemelli F., Pasqualini L., Vaudo G., Marchesi S., et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J. Hypertens. 21 (2003) 1841-1846
20. Sesso H.D., Buring J.E., Rifai N., Blake G.J., Gaziani J.M., and Ridker P.M. C-reactive protein and the risk of developing hypertension. JAMA 290 (2003) 2945-2951
21. Blake G.J., Rifai N., Buring J.E., and Ridker P.M. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 108 (2003) 2993-2999
22. Bautista L.E., Atwood J.E., O'Malley P.G., and Taylor A.J. Association between C-reactive protein and hypertension in healthy middle-aged men and women. Coron. Artery Dis. 15 (2004) 331-336
23. Rasouli M., Kiasari A.M., and Mokhberi V. The ratio of apoB/apoAI, apoB and Lp(a) are the best predictors of stable coronary artery disease. Clin. Chem. Lab. Med. 44 (2006) 1015-1021
24. Saito M., Ishimitsu T., Minami J., Ono H., Ohrui M., and Matsuoka H. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 167 (2003) 73-79
25. Rasouli M., and Kiasari A.M. Association of serum calcium and phosphorus to the occurrence and severity of angiographically documented coronary heart disease, possibly through correlation with atherogenic lipids and (apo)lipoproteins. Clin. Chem. Lab. Med. 44 (2006) 43-50
26. Albert M.A., Glynn R.J., and Ridker P.M. Plasma concentration of C-reactive protein and calculated Framingham coronary heart disease risk score. J. Am. Coll. Cardiol. 319A (2003) 889-896 [Abs]
27. Rogowski O., Shapira I., Toker S., Melamed S., Shirom A., Berliner S., et al. Obesity-related correlation between C-reactive protein and the calculated 10-y Framingham coronary heart disease risk score. Int. J. Obes. 29 (2005) 772-777
28. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342 (2000) 836-843
29. Ridker P.M., Glynn R.J., and Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97 (1998) 2007-2011
30. Rifai N., and Ridker P.M. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin. Chem. 47 (2001) 28-30
31. Piché M.P., Lemieux S., Weisnagel S.J., Corneau L., Nadeau A., and Bergeron J. Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women. Am. J. Cardiol. 96 (2005) 92-97
32. Lee W.Y., Park J.S., Noh S.Y., Rhee E.J., Sung K.C., Kim M.S., et al. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report. Int. J. Cardiol. 97 (2004) 101-106
33. Ridker P.M., Buring J.E., Cook N.R., and Rifai N. C-reactive protein, metabolic syndrome, and risk of incident cardiovascular events. An 8-year follow-up of 14719 initially healthy American women. Circulation 107 (2003) 391-397
34. Yudkin J.S., Juhan-Vague I., Hawe E., Humphries S.E., Minno di G., Margaglione M., et al. Low grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 53 (2004) 852-857
35. Schmidt M.I., Duncan B.B., Sharret A.R., Lindberg G., Savage P.J., Offenbacher S., et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 353 (1999) 1649-1652
36. Bautista L.E., Lopez-Jaramillo P., Vera L.M., Casas J.P., Otero A.P., and Guaracao A.I. Is C-reactive protein an independent risk factor for essential hypertension?. J. Hypertens. 19 (2001) 857-861
37. Sinisalo J., Paronen J., Mattila K.J., Syrjala M., Alfthan G., Palosuo T., et al. Relation of inflammation to vascular function in patients with coronary heart disease. Atherosclerosis 149 (2000) 403-411
38. Sung K.C., Suh J.Y., Kim B.S., Kang J.H., Kim H., Lee M.H., et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am. J. Hypertens. 16 (2003) 429-433
39. Bhagat K., and Vallance P. Inflammatory cytokines impair endothelium dependent dilation in human veins in vivo. Circulation 96 (1997) 3042-3047